mRNA-1468
- Generic Name
- mRNA-1468
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
Phase 1
Active, not recruiting
- Conditions
- Herpes Zoster
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 659
- Registration Number
- NCT05701800
- Locations
- 🇺🇸
Velocity Clinical Research - Westlake, Los Angeles, California, United States
🇺🇸Tekton Research, Inc - Longmont Center, Longmont, Colorado, United States
🇺🇸Meridien Research, Lakeland, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath